vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $99.5 million.
- vTv Therapeutics' Liabilities and Shareholders Equity rose 13050.23% to $99.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 2674.8%. This contributed to the annual value of $38.3 million for FY2024, which is 24730.44% up from last year.
- As of Q3 2025, vTv Therapeutics' Liabilities and Shareholders Equity stood at $99.5 million, which was up 13050.23% from $26.4 million recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' Liabilities and Shareholders Equity registered a high of $99.5 million during Q3 2025, and its lowest value of $11.0 million during Q4 2023.
- For the 5-year period, vTv Therapeutics' Liabilities and Shareholders Equity averaged around $33.6 million, with its median value being $31.4 million (2021).
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 34612.55% in 2021, then tumbled by 6685.12% in 2023.
- vTv Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $25.5 million in 2021, then surged by 30.48% to $33.2 million in 2022, then crashed by 66.85% to $11.0 million in 2023, then skyrocketed by 247.3% to $38.3 million in 2024, then surged by 160.01% to $99.5 million in 2025.
- Its last three reported values are $99.5 million in Q3 2025, $26.4 million for Q2 2025, and $32.0 million during Q1 2025.